Lates News

China Biopharmaceuticals announced that the clinical trial application for TQF3250 capsules, a GLP-1 receptor agonist, has been accepted by the NMPA. This drug is mainly metabolized by CYP3A enzymes with low risk of drug interactions. Currently, there is only one oral GLP-1RA approved for marketing globally. The group will accelerate the clinical development of TQF3250 to provide a more convenient and effective treatment option for type 2 diabetes patients.